Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Agenda who wrote (4041)	10/25/2000 1:26:29 PM
From: DELT1970	Read Replies (1) \| Respond to of 4140

October 25, 2000, Lehman Bros Sunrise Technologies (SNRS - $6 3/8) 1 - Buy Company Update Positive Vibes from the AAO! Stock Overview Investment Conclusion We reiterate our 1-Buy rating of Sunrise Technologies due to the demonstrated high demand for the Hyperion laser units and early anecdotal evidence of high utilization that was evident at this week’s AAO meeting. We believe that Sunrise will meet our expectations of 115 unit sales by end of year with a loss of ($0.46) EPS for 00E. Going forward we anticipate top line growth to $81.4M FY01 (+300%), with expanding margins due to favorable product mix as more procedures are performed per unit. We anticipate break even in 1Q01 with EPS $0.19 01E. Value will be realized as more units are shipped, public demand for “no touch” laser correction is demonstrated and the stock attracts the attention of more investors. Summary Unmet needs remain clearly evident Capital placements, a leading indicator of procedures, remain in-line with high expectations Opinion leaders in ophthalmology successfully rebutting negative investor driven perception of LTK with data and personal experience UNMET NEEDS REMAIN CLEARLY EVIDENT: Hyperion LTK is approved for the reduction of up to 2.5 diopters of hyperopia in patients older than 40 years. Approximately 38 million Americans are eligible candidates for this procedure. The “unconvinced” observe that only 5- 15% of patients undergoing LASIK are hyperopic, thus concluding that the hyperopia market will not be as robust as that for myopia. However, anecdotal evidence suggests that doctors who have purchased the Hyperion units in the last quarter are exceeding their own estimates in demand. This despite the fact that as small businesses, the doctor- entrepreneurs, have not yet started a marketing effort aimed away from the young myopic LASIK patient to one targeting the older (over 40 year old) hyperopic patient. CAPITAL PLACEMENTS, A LEADING INDICATOR OF PROCEDURES, REMAIN IN-LINE WITH HIGH EXPECTATIONS. In 3Q00, the company sold 48 Hyperion laser units, falling slightly short of our expectations. This was probably caused by a shortened third quarter due to FDA approval during the July 4th holiday and the finalization of the “lease per procedure” model early in the period. The company did ship additional units late in the quarter, but will only recognize revenue after completed installation (4Q00). Sunrise officers appeared satisfied with their impact at the American Academy of Ophthalmology meeting in Dallas (10/20/00-10/26/00) and their first opportunity to sell units at the largest ophthalmology meeting of the year. Doctors who already own Hyperion lasers met twice at informal scientific sessions and appeared enthusiastic about Sunrise LTK. We believe that with the opportunity of a full (fourth)quarter ahead, punctuated by the prospects of strong sales at the AAO this week, the company will meet our sales expectations of 115 units for the year. We think that the rapid ramp in laser unit sales is the best forward indicator of procedure growth and demonstrates a clear commitment on the part of the MD purchasers. We note that in 1997 the demand for excimer lasers was such that only 87 excimer units (VISX & Summit combined) were placed in the U.S. The following year, U.S. laser vision correction grew by nearly 50% to 400k procedures. OPINION LEADERS IN OPHTHALMOLOGY SUCCESSFULLY REBUTTING NEGATIVE INVESTOR DRIVEN PERCEPTION OF LTK WITH DATA AND PERSONAL EXPERIENCE Interestingly, a number of ophthalmologists had formed their opinion of the Sunrise LTK procedure by reading the financial pages which have been replete with negative investor sentiment. The face to face meeting of MD opinion leaders with skeptical doctors at this week’s AAO has given Sunrise an opportunity to confront the doubting doctors with data comparing the different modalities available for hyperopia with regards to visual outcomes and late regression of effect. The Sunrise LTK compares favorably to the competition at a lower cost and lower complication profile. This represents a powerful opportunity to convert the uninitiated to a more positive view leading to more sales and fewer nay-sayers.